Am J Transplant, Volume 20, Suppl 3 Archives - Page 58 of 223 - ATC Abstracts

2020 American Transplant Congress
Virtual XM Adversely Affects Access for Highly Sensitized African Americans Awaiting Renal Transplantation
P. T. Jindra¹, B. V. Murthy¹, C. Van Buren²
¹Surgery, Baylor College of Medicine, Houston, TX, ²Surgery, UT Medical School, Houston, TX
*Purpose: Recent UNOS policy proposals have changed kidney allocation from local Designated Service Areas (DSA) to geographic distribution areas of varying widths. Since crossmatch of…
2020 American Transplant Congress
Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
M. Ohira¹, R. Hotta¹, Y. Imaoka¹, K. Sato¹, N. Tanimine¹, H. Tahara¹, K. Ide¹, T. Kobayashi¹, Y. Tanaka¹, A. Tzakis², S. Nishida², H. Ohdan¹
¹Hiroshima University, Hiroshima, Japan, ²University of Miami, Miami, FL
*Purpose: Development of an effective adjuvant therapy to prevent HCC recurrence after liver transplantation (LT) is an important medical requirement. Immunosuppressive regimens currently used after…
2020 American Transplant Congress
Re-Examining Sex-Based Differences in Liver Transplant Outcomes for HCV Cirrhosis
D. Yoeli¹, R. Choudhury¹, H. Moore¹, A. Sauaia¹, M. Simpson², E. Pomfret¹, T. Nydam¹
¹Transplant Surgery, University of Colorado, Aurora, CO, ²Transplant Surgery, Lahey Hospital and Medical Center, Burlington, MA
*Purpose: Previous studies have demonstrated that female liver transplant recipients with hepatitis C (HCV) are at increased risk for graft failure due to disease recurrence…
2020 American Transplant Congress
Pharmacy Led Initiatives for Treatment of Transplant Recipients of Hepatitis C Viremic Donors in a High Volume Transplant Center
H. Berry, J. Byrns, L. Crona, T. Capes, J. M. Steinbrink, E. K. Maziarz, C. R. Wolfe
Duke University Medical Center, Durham, NC
*Purpose: We describe a multidisciplinary workflow for initiation of hepatitis C virus (HCV) direct-acting antiviral (DAA) therapies post-transplant in the outpatient setting of a high…
2020 American Transplant Congress
Effects of Donor Specific Antibodies in Intestinal/Multivisceral Transplant Recipients
K. Klein¹, M. Keck², E. Langewisch², S. Merani², M. Leick²
¹University Health System, San Antonio, TX, ²Nebraska Medicine, Omaha, NE
*Purpose: Evaluate the effects of donor specific antibodies (DSAs) on outcomes in post-intestinal/multivisceral (MV) transplant patients and describe the presentation of DSAs post-transplant.*Methods: This single-center…
2020 American Transplant Congress
Donor-Derived DCREG Infusion Prolongs Kidney Allograft Survival in Rhesus Monkeys Treated with Co-Stimulation Blockade and Calcineurin Inhibition
Y. Wang, S. Kazuki, L. Lu, A. Zahorchak, H. Dai, A. Ganoza, M. Wijkstrom, A. Humar, M. Ezzelarab, A. Thomson
Thomas E. Starzl Transplantation Institute, Pittsburgh, PA
*Purpose: We have shown previously that pre-transplantation (Tx) infusion of donor-derived regulatory dendritic cells (DCreg) safely prolongs MHC-mismatched renal allograft survival and regulates donor-reactive T…
2020 American Transplant Congress
Impact of Extended- versus Immediate-Release Tacrolimus on One-Year Development of De Novo DSA and Chronic Immune Activation in Kidney Transplantation (ASTOUND Study)
A. Wiseman¹, D. Kaufman², A. Patel³, D. Wojciechowski⁴, A. Tambur⁵, J. Kim⁶, J. Schwartz⁶
¹University of Colorado Hospital, Aurora, CO, ²University of Wisconsin, Madison, WI, ³Henry Ford Hospital, Detroit, MS, ⁴Massachusetts General Hospital, Boston, MA, ⁵Northwestern University, Chicago, IL, ⁶Astellas Pharma Global Development, Northbrook, IL
*Purpose: To compare, using an adaptive study design, the 1-year incidence of a novel two-part composite endpoint consisting of de novo donor-specific antibody (dnDSA) formation…
2020 American Transplant Congress
Feasibilty of Hepatitis C NAT Positive Kidney Transplant into Hepatitis C Negative Recipients as Standard of Care
T. Kaur, J. Choi, N. Anwar, M. Anand, S. Shah, S. Bumb, B. Abu Jawdeh, S. Shah, T. Diwan, A. Govil
University of Cincinnati Medical Center, Cincinnati, OH
*Purpose: With advent of direct acting antivirals (DAA) for Hepatitis (Hep) C which have a 96-100% sustained viral remission(SVR), doors have opened for using Hep…
2020 American Transplant Congress
Recipient and Donor Factors Associated with Post-Donation ESRD in Related White Living Kidney Donors
J. Wainright¹, A. Robinson¹, A. Wilk¹, D. Klassen², W. Cherikh¹, L. Cartwright¹, D. Stewart¹
¹Research, UNOS, Richmond, VA, ²Chief Medical Officer, UNOS, Richmond, VA
*Purpose: We studied post-donation ESRD in white first-degree related living kidney donors (RLKDs) in the US between 1994 and 2018 (n=45700); this study is the…
2020 American Transplant Congress
Antibodies to Vascular Autoantigens Are Associated with Poor Long-Term Survival of Liver Re-Transplant
Q. Xu¹, V. C. McAlister², S. Leckie², A. A. House², A. Zeevi¹
¹Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Multiorgan Transplant Program, London Health Sciences Centre, London, ON, Canada
*Purpose: Autoantibodies, which may be generated in transplantation through the exposure of cryptic antigens, are reported to be detrimental for allograft survival. We have demonstrated…